SOA101 is a nanobody-based trispecific antibody T cell engager (Nb-TriTE),
the first broad-spectrum trispecific antibody drug successfully developed under platform technology ”Trispecific T cell engager antibody” for the treatment of lung cancer, colorectal cancer, breast cancer, head and neck cancer, and ovarian cancer.SOA101 precisely targets the dual immune checkpoints PD-L1 and HLA-G on tumor cells while engaging and activating T cells, enhancing the effectiveness of cancer immunotherapy and mitigating drug resistance.
SOA101 achieves three world-firsts:
1) Dual immune checkpoint inhibitor for cancer treatment;
2) Trispecific antibody drug targeting HLA-G;
3) Nanobody-based tri-specific antibody drug against cancer.
ShineOn has completed a FDA Pre-IND consultation and received positive feedback in Jan 2024.
.jpg)